GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Cash Flow from Investing

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Cash Flow from Investing : ¥-1,240 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Shenzhenlubris Pharmaceuticals Co spent ¥114 Mil on purchasing property, plant, equipment. It gained ¥0 Mil from selling property, plant, and equipment. It spent ¥0 Mil on purchasing business. It gained ¥0 Mil from selling business. It spent ¥150 Mil on purchasing investments. It gained ¥158 Mil from selling investments. It paid ¥0Mil for net Intangibles purchase and sale. And it paid ¥0 Mil for other investing activities. In all, Shenzhenlubris Pharmaceuticals Co spent ¥107 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Shenzhenlubris Pharmaceuticals Co Cash Flow from Investing Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Cash Flow from Investing Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -212.31 -849.44 -369.65 -1,273.31 -1,370.82

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -237.58 -160.46 -392.51 -580.29 -106.55

Shenzhenlubris Pharmaceuticals Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Shenzhenlubris Pharmaceuticals Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Shenzhenlubris Pharmaceuticals Co's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,240 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Shenzhenlubris Pharmaceuticals Co's purchase of property, plant, equipment for the three months ended in Mar. 2024 was ¥-114 Mil. It means Shenzhenlubris Pharmaceuticals Co spent ¥114 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Shenzhenlubris Pharmaceuticals Co's sale of property, plant, equipment for the three months ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co gained ¥0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Shenzhenlubris Pharmaceuticals Co's purchase of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co spent ¥0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Shenzhenlubris Pharmaceuticals Co's sale of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co gained ¥0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Shenzhenlubris Pharmaceuticals Co's purchase of investment for the three months ended in Mar. 2024 was ¥-150 Mil. It means Shenzhenlubris Pharmaceuticals Co spent {stock_data.stock.currency_symbol}}150 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Shenzhenlubris Pharmaceuticals Co's sale of investment for the three months ended in Mar. 2024 was ¥158 Mil. It means Shenzhenlubris Pharmaceuticals Co gained ¥158 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Shenzhenlubris Pharmaceuticals Co's net Intangibles purchase and sale for the three months ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co paid ¥0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Shenzhenlubris Pharmaceuticals Co's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Shenzhenlubris Pharmaceuticals Co paid ¥0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Shenzhenlubris Pharmaceuticals Co's cash from other investing activities for the three months ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co paid ¥0 Mil for other investing activities.


Shenzhenlubris Pharmaceuticals Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines